Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07021989CT.gov ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT06919679CT.gov Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07002216CT.gov BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT07234487CT.gov Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL | — | Recruiting | — | — | — |
NCT06831370CT.gov A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India | — | Recruiting | — | — | — |
NCT06377566CT.gov A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT05922904CT.gov PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05675410CT.gov A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | — | Recruiting | — | — | — |
NCT06201507CT.gov BV-AVD-R Treatment Children Hodgkin's Lymphoma | — | Unknown | — | — | — |
NCT04685616CT.gov Brentuximab Vedotin in Early Stage Hodgkin Lymphoma | — | Recruiting | — | — | — |
Show 62 more trialsShow fewer
NCT05253495CT.gov Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma | — | Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03907488CT.gov Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03517137CT.gov Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study | — | Active Not Recruiting | — | — | — |
NCT03646123CT.gov Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT03755804CT.gov Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | — | Active Not Recruiting | — | — | — |
NCT03712202CT.gov Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03618550CT.gov Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT03407144CT.gov Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | — | Active Not Recruiting | — | — | — |
NCT03527628CT.gov OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy | — | Unknown | — | — | — |
NCT03233347CT.gov Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03500133CT.gov Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation. | — | Recruiting | — | — | — |
NCT02979522CT.gov A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02800447CT.gov Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol | — | Unknown | — | — | — |
NCT02613598CT.gov Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma | — | Completed | — | — | — |
NCT02356159CT.gov Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | — | Completed | — | — | — |
NCT02505269CT.gov Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02398240CT.gov Brentuximab for Newly Diagnosed Hodgkin Disease | — | Completed | — | — | — |
NCT02298283CT.gov Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD | — | Completed | — | — | — |
NCT02166463CT.gov Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02292979CT.gov Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. | — | Completed | — | — | — |
NCT02362035CT.gov ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | — | Completed | — | — | — |
NCT02208037CT.gov Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | — | Completed | — | — | — |
NCT01920932CT.gov Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01897012CT.gov Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | — | Completed | — | — | — |
NCT01868451CT.gov Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02275598CT.gov Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT01771107CT.gov Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01858922CT.gov Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A | — | Completed | — | — | — |
NCT01712490CT.gov A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01569204CT.gov Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01567709CT.gov Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | — | Completed | — | — | — |
NCT01578967CT.gov Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01534078CT.gov Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02247869CT.gov Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT01356680CT.gov HD17 for Intermediate Stage Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01476410CT.gov Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00797472CT.gov Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease | — | Unknown | — | — | — |
NCT01523847CT.gov A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL) | — | Completed | — | — | — |
NCT01060904CT.gov A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01026220CT.gov Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01030900CT.gov Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas | — | Completed | — | — | — |
NCT00994500CT.gov Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma | — | Completed | — | — | — |
NCT00933985CT.gov Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | — | Terminated | — | — | — |
NCT00837200CT.gov Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies | — | Terminated | — | — | — |
NCT00791011CT.gov Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat | — | Completed | — | — | — |
NCT00520130CT.gov Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | — | Completed | — | — | — |
NCT00439361CT.gov Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00352027CT.gov Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00337194CT.gov SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | — | Completed | — | — | — |
NCT00348985CT.gov PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | — | Completed | — | — | — |
NCT00302003CT.gov Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00096005CT.gov Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | — | Terminated | — | — | — |
NCT01468740CT.gov Prospective Study on HIV-related Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT00284271CT.gov Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma | — | Completed | — | — | — |
NCT00025259CT.gov Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease | — | Completed | — | — | — |
NCT00038558CT.gov Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy | — | Completed | — | — | — |
NCT00145600CT.gov Therapy for Pediatric Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01251107CT.gov Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00265031CT.gov HD12 for Advanced Stages | — | Completed | — | — | — |
NCT00264953CT.gov HD11 for Intermediate Stages | — | Completed | — | — | — |
NCT00592111CT.gov A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hodgkins Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | M.D. Anderson Cancer Center | Approved | BB · 70 |
| Everolimus | OHSU Knight Cancer Institute | P2 | BBB |
| Carboplatin | St. Petersburg State Pavlov Medical University | P2 | BBB |
| Camustine | VIVUS LLC | P2 | BBB |
| Isocyclophosphamide | St. Petersburg State Pavlov Medical University | P3 | BBB |
| Cyclosporin A | City of Hope Medical Center | P3 | BBB |
| Vinorelbine Ditartrate | Michael Spinner, MD | P3 | BBB |
| Vinblastine | M.D. Anderson Cancer Center | P4 | BBB |
| Vincristine Sulfate | National Cancer Institute (NCI) | P3 | BBB |
+42 more in the Hodgkins Lymphoma cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adriamycin in Hodgkins Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-hodgkins-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →